LifeMD Sets Q4 Revenue Outlook at $46 Million to $49 Million

LifeMD, Inc. (LFMD) set fourth-quarter 2026 revenue guidance at $46 million to $49 million after third-quarter sales of $44.6 million came in below its previously guided range. The company also set a goal of reducing operating expenses by 30% by the first quarter of 2027.

LifeMD lowered its full-year 2026 revenue outlook to $188 million to $191 million and expects an adjusted EBITDA loss of $10.6 million to $12.6 million. For the fourth quarter, it forecast an adjusted EBITDA loss of $2 million to $4 million.

Chairman and CEO Justin Schreiber said, “We now expect to exit at roughly a $200 million revenue run rate.” LifeMD expects its patient base and revenue to grow about 30% in 2027, while excluding enterprise efforts and new pharmacy products from near-term guidance.

LifeMD cited arrangements with Eli Lilly and Novo Nordisk, an active collaboration with AT&T, pharmacy growth and discussions with more than 10 virtual platforms. The company announced a mail-order option for Eli Lilly’s Zepbound and Foundayo on Nov. 5.

LifeMD said gross margin declined to about 82%, primarily reflecting a change in presentation rather than economics. It also said branded GLP-1 products add gross profit and EBITDA. The company ended the quarter with $21.9 million in cash and no debt, and expects sufficient capital for working-capital needs.